NCT02312037No Longer AvailableNot Applicable
GEMTUZUMAB OZOGAMICIN (MYLOTARG (REGISTERED)) EXPANDED ACCESS PROTOCOL FOR TREATMENT OF PATIENTS IN THE UNITED STATES WITH RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA WHO MAY BENEFIT FROM TREATMENT AND HAVE NO ACCESS TO OTHER COMPARABLE/ALTERNATIVE THERAPY
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- No Longer Available
- Sponsor
- Pfizer
- Locations
- 135
Study Overview
Brief Summary
An expanded access/compassionate use protocol that allows access to Mylotarg for relapsed/refractory AML CD33 positive patients in the USA.
Contact: B1761026@iconplc.com
Detailed Description
Contact:
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
- Ages
- 3 Months to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Confirmed diagnosis of relapsed/refractory AML (defined as >=5% marrow blasts by morphology), including MDS, with persisting rising blasts and no other comparable or satisfactory alternative therapy available. If bone marrow has <5% blasts by morphology but the patient has evidence of relapse with extra-medullary disease progression. In select cases presenting with conversion of MRD from negative to positive, treatment with GO may be allowed where no alternative treatments are feasible.
- •Confirmed diagnosis of relapsed or refractory APL with persisting or rising leukemic burden (either by morphology, cytogenetic analysis or by molecular techniques), and no other comparable or satisfactory alternative therapy available.
- •Documentation that malignant cells express CD33
- •Age >=3 months
- •Adequate non-hematologic organ function
Exclusion Criteria
- •Untreated AML and MDS or AML and MDS in complete remission.
- •Patients with a known history of VOD/SOS.
- •Patients with a known hypersensitivity to Mylotarg or its parts: hP67.6 antibody, calicheamicin derivatives or other ingredients.
- •Participation in other studies involving investigational drug(s) (Phases 1-4) during study participation.
Investigators
Study Sites (135)
Loading locations...
Similar Trials
Approved For Marketing
Not Applicable
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Promyelocytic Leukemia (M3)Childhood Acute Promyelocytic Leukemia (M3)Recurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid LeukemiaNCT01869803Wake Forest University Health Sciences
Available
Not Applicable
Expanded Access to Gallium Maltolate (GaM)Refractory GlioblastomaGlioblastoma MultiformeGlioblastomaNCT06404034Imaging Biometrics, LLC
Completed
Phase 2
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDSAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT00195000Weill Medical College of Cornell University43
Approved For Marketing
Not Applicable
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCLDLBCLNCT04300803MorphoSys AG
Completed
Not Applicable
Mylotarg as salvage treatment for children with relapsed acute myeloid leukemia.acute myeloid leukemia, AML, gemtzuzumab ozogamicin, mylotarg, children, relapseNL-OMON21108VUmc, Amsterdam50